The BT share price soars by 20%. Here’s why I think it could beat the FTSE 100

BT Group plc (LON: BT.A) could offer further growth potential versus the FTSE 100 (INDEXFTSE:UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What a difference six months can make. That’s how long it has taken for the BT (LSE: BT.A) share price to gain 20%. And it has come at a time when the FTSE 100 has dropped significantly, with fears surrounding the prospects for the world economy holding back its performance.

Looking ahead, BT may continue to recover. It has appointed a new CEO, is delivering on its cost-reduction strategy and still appears to have a low valuation. Here’s why it could continue to outperform the FTSE 100 alongside another stock that released a positive update on Thursday.

Improving prospects

The company in question is multinational pharmaceutical group Hikma (LSE: HIK). It released a trading update having delivered strong performance since the start of the financial year. It has raised its guidance for the full year, delivering revenue and profit growth which is ahead of its expectations. Both its Generics and Injectables businesses are performing well, while in the MENA region, its Branded business is continuing to grow steadily. It is continuing to benefit from new product launches, as well as a diversified product range.

Alongside its trading update, the company also released news of a partnership with Vectura. It will develop and commercialise the company’s Open, Inhale, Close (OIC) dry product inhaler platform. With the generic respiratory market being a key growth area for Hikma, this could lead to improving prospects over the long term.

While the stock has a price-to-earnings (P/E) ratio of around 23, it seems to offer growth potential due to its improving financial prospects. Having gained 105% in the last year, the stock could post further capital growth.

Recovery potential

As mentioned, the BT share price has enjoyed a very positive six-month period. Its recent update showed that it has started to implement an aggressive strategy change which has seen 2,000 roles made redundant already. Further job cuts are ahead and, while they are painful for those involved, they could create a stronger business over the medium term.

The company has also announced the appointment of a new CEO. Although there is a risk that he will seek to make major changes and this could cause instability, the progress that is seemingly being made as a new strategy is delivered may mean that the company is in a stronger position by the start of 2019.

Despite its 20% rise in the last six months, BT continues to have a price-to-earnings (P/E) ratio of 9. This indicates that it may still be trading at a discount to its intrinsic value, which could suggest there is more scope for growth. Although it may have been one of the FTSE 100’s more disappointing shares in previous years, a new strategy and new management team could catalyse the company’s future performance. While uncertainty remains, it has the potential to keep beating the FTSE 100.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Hikma Pharmaceuticals. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Here’s my plan for long-term passive income

On the lookout for passive income stocks to buy, Stephen Wright is turning to one of Warren Buffett’s most famous…

Read more »

artificial intelligence investing algorithms
Growth Shares

Are British stock market investors missing out on the tech revolution?

British stock market investors continue to pile into ‘old-economy’ stocks. Is this a mistake in today’s increasingly digital world?

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

My 2 best US growth stocks to buy in November

I’ve just bought two US growth companies on my best stocks to buy now list, and I think they’re still…

Read more »

Investing Articles

£2k in savings? Here’s how I’d invest that to target a passive income of £4,629 a year

Harvey Jones examines how investing a modest sum like £2,000 and leaving it to grow for years can generate an…

Read more »

Renewable energies concept collage
Investing Articles

Down 20%! A sinking dividend stock to buy for passive income?

This dividend stock is spending £50m buying back its own shares while they trade at a discount and also planning…

Read more »

Investing Articles

I’d buy 32,128 shares of this UK dividend stock for £200 a month in passive income

Insider buying and an 8.1% dividend yield suggest this FTSE 250 stock could be a good pick for passive income,…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

As stock markets surge, here’s what Warren Buffett’s doing

Warren Buffett has been selling his largest investments! Should investors follow in his footsteps, or is there something else going…

Read more »

Investing Articles

£50k in savings? Here’s how I’d aim to turn that into a £30k second income!

Investing in stocks is a great way to earn a second income, but relying on index funds may not be…

Read more »